Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Corneal Persistent Epithelial Defect
Conditions
Corneal Persistent Epithelial Defect
Trial Timeline
Jun 30, 2020 → Feb 7, 2022
NCT ID
NCT04081103About Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen) is a phase 2 stage product being developed by Glaukos for Corneal Persistent Epithelial Defect. The current trial status is terminated. This product is registered under clinical trial identifier NCT04081103. Target conditions include Corneal Persistent Epithelial Defect.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04081103 | Phase 2 | Terminated |
Competing Products
12 competing products in Corneal Persistent Epithelial Defect
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution | Santen Pharmaceutical | Phase 2 | 52 |
| Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1% | AbbVie | Phase 2 | 52 |
| 0.3% hypromellose | Novartis | Approved | 85 |
| Mycophenolate Mofetil 2x 1g | Roche | Approved | 85 |
| Subconjunctival aflibercept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system | Glaukos | Phase 3 | 74 |
| lufepirsen high dose + Vehicle + lufepirsen low dose | Glaukos | Phase 2 | 49 |
| OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo | Oculis Holding AG | Phase 2 | 47 |
| DT-168 | Design Therapeutics | Phase 2 | 47 |
| KPI-012 + KPI-012 Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |
| loteprednol etabonate 0.25% ophthalmic suspension | Kala Pharmaceuticals | Approved | 77 |
| QR-504a | ProQR | Phase 1 | 25 |